Atriva Fast Tracks Antiviral Candidate As Coronavirus Arrives In Germany
Working With Doctors To Test Against Virus
The antiviral specialist says MEK inhibitor could work against 2019-nCoV, but tests will take time.
You may also be interested in...
Codagenix, a company backed by Novartis, Merck and the Bill & Melinda Gates Foundation, has tied up with India’s Serum Institute to develop a vaccine against SARS-CoV-2, joining a heated race against the dreaded COVID-19 outbreak.
The venture capital firm is putting $210m into NSCLC trials for the antibody drug conjugate – with an opportunity in patients who fail on first line immunotherapy the most likely target.
The European biotech is just getting started with its expansion plans for the drug in generalized myasthenia gravis, while multiple readouts in new autoimmune diseases are expected in 2024.